Latest Intellectual Property News

HyTerra Limited has begun trading on the US OTCQB Venture Market, opening doors to American investors and supporting its strategic expansion in the burgeoning geologic hydrogen sector.

PlaySide Studios reported a tough FY25 with a 25% revenue drop and a $7.4 million EBITDA loss, prompting a swift restructure. The company is optimistic about FY26, driven by strong original IP titles and expanding external projects.

Hazer Group has made significant strides in commercialising its methane pyrolysis technology, advancing key partnerships and strengthening its intellectual property portfolio amid a tightening global graphite market.

Noxopharm Limited has been granted its first US patent for the Sofra™ technology platform, marking a key milestone in its cancer immunotherapy research. This patent protects the company’s innovative immune-modulatory oligonucleotides, underpinning its expanding pipeline in a rapidly growing market.

Weebit Nano has reported a fourfold revenue increase in FY25, driven by a landmark licensing agreement with semiconductor giant onsemi and key automotive-grade qualification for its ReRAM technology.

Weebit Nano has reported a record quarter with A$7.3 million in customer receipts, securing three key product agreements and progressing critical technology milestones at leading semiconductor fabs.

Invion Limited has partnered with Protect Animal Health to explore Photosoft™, a novel photodynamic therapy, as a treatment for cancer in companion animals, targeting a booming pet cancer market.

Iondrive Limited has inked a binding term sheet with LAT66 Limited to apply its innovative Deep Eutectic Solvent technology to cobalt-rich concentrates from Finland’s Kuusamo projects, marking a strategic step beyond battery recycling into primary mineral processing.

Neurizon Therapeutics has been granted a key Australian patent for its lead drug candidate NUZ-001, extending protection for treatments targeting ALS, Alzheimer's, and other neurodegenerative diseases through 2041. This milestone complements earlier US patent grants and sets the stage for upcoming clinical trials.

Etherstack has secured a £14.2 million contract with the UK Home Office to provide critical software for the Emergency Services Network, reinforcing its global leadership in public safety communications.

Mesoblast Limited reports a 69% jump in net revenues from its pioneering cell therapy Ryoncil in Q1 FY2026, propelled by expanded physician adoption and new reimbursement pathways. The company also secures convertible note funding and plans pivotal adult trials.

Wellnex Life reported an 18.2% sales decline in Q1 FY26 amid delayed IP licensing revenue and increased costs, while securing new debt facilities and exiting the medicinal cannabis segment.